IPO registrations (S-1, F-1) · Registrants
Revance Therapeutics, Inc.
- SEC CIK
- 1479290 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2013-12-31, last 2014-06-18; 2 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2014-02-06; declared effective 2014-02-05
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1222 DEMONBREUN STREET, SUITE 2000, Nashville, TN 37203
- EIN
- 77-0551645
- EDGAR entity type
- operating
- Insiders and CEO pay
- Revance Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2014-02-03)
- Final price
- $16.00 per share, within the range (424B4 filed 2014-02-06, an initial public offering)
- Shares sold
- 6,000,000
- Gross proceeds
- $96,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol RVNC
- Lead underwriters
- Cowen; Piper Sandler
- Syndicate
- BMO Capital Markets
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: REVANCE THERAPEUTICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Revance Therapeutics, Inc. Fuzzy (name and state)
- Business registration: REVANCE THERAPEUTICS, INC Fuzzy (name and state)
- Business registration: REVANCE THERAPEUTICS, INC Fuzzy (name and state)
- Business registration: REVANCE THERAPEUTICS, INC. Fuzzy (name and state)
- Business registration: REVANCE THERAPEUTICS, INC. Fuzzy (name and state)
- Business registration: REVANCE THERAPEUTICS, INC. Fuzzy (name and state)
- Business registration: REVANCE THERAPEUTICS, INC. Fuzzy (name and state)
- Business registration: REVANCE THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: REVANCE THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Federal award recipient: REVANCE THERAPEUTICS, INC. Fuzzy (name and state)
- Lobbying client: REVANCE THERAPEUTICS INC. Fuzzy (name and state)
- SEC filer: Revance Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 14
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-12-31 | S-1 | S-1 (registration) | Revance Therapeutics, Inc. | 0001193125-13-488614 ↗ |
| 2014-01-27 | S-1/A | S-1/A (amendment) | Revance Therapeutics, Inc. | 0001193125-14-020967 ↗ |
| 2014-02-03 | S-1/A | S-1/A (amendment) | Revance Therapeutics, Inc. | 0001193125-14-033118 ↗ |
| 2014-02-05 | S-1MEF | S-1MEF (added securities) | Revance Therapeutics, Inc. | 0001193125-14-037365 ↗ |
| 2014-02-05 | EFFECT | EFFECT (declared effective) | Revance Therapeutics, Inc. | 9999999995-14-000330 ↗ |
| 2014-02-06 | 424B4 | 424B4 (final prospectus) | Revance Therapeutics, Inc. | 0001193125-14-037802 ↗ |
| 2014-06-06 | S-1 | S-1 (registration) | Revance Therapeutics, Inc. | 0001193125-14-228901 ↗ |
| 2014-06-16 | S-1/A | S-1/A (amendment) | Revance Therapeutics, Inc. | 0001193125-14-237646 ↗ |
| 2014-06-18 | S-1/A | S-1/A (amendment) | Revance Therapeutics, Inc. | 0001193125-14-240667 ↗ |
| 2014-06-18 | EFFECT | EFFECT (declared effective) | Revance Therapeutics, Inc. | 9999999995-14-001822 ↗ |
| 2014-06-19 | 424B4 | 424B4 (final prospectus) | Revance Therapeutics, Inc. | 0001193125-14-241675 ↗ |
| 2015-03-18 | EFFECT | EFFECT (declared effective) | Revance Therapeutics, Inc. | 9999999995-15-000633 ↗ |
| 2015-11-02 | EFFECT | EFFECT (declared effective) | Revance Therapeutics, Inc. | 9999999995-15-002935 ↗ |
| 2016-03-25 | EFFECT | EFFECT (declared effective) | Revance Therapeutics, Inc. | 9999999995-16-004046 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-02-03 | S-1/A | registration statement | $14.00–$16.00 | 5,000,000 | - | Nasdaq RVNC | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2014-02-06 | 424B4 | final prospectus | $16.00 | 6,000,000 | $96,000,000 | Nasdaq RVNC | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Browne L Daniel | Director,Officer | CEO and President | 36 | 2014–2019 | |
| BYRNES ROBERT F | Director | 11 | 2014–2020 | ||
| Eastman Ronald W | Director,TenPercentOwner | 6 | 2014–2017 | ||
| ESSEX WOODLANDS HEALTH VENTURES FUND VIII-A LP | TenPercentOwner | 3 | 2014 | ||
| ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B LP | TenPercentOwner | 3 | 2014 | ||
| ESSEX WOODLANDS HEALTH VENTURES FUND VIII LP | TenPercentOwner | 3 | 2014 | ||
| GARDNER PHYLLIS | Director | 10 | 2014–2020 | ||
| Glasheen James Walter | Director | 5 | 2014–2016 | ||
| NovaQuest Pharma Opportunities Fund III, L.P. | TenPercentOwner | 4 | 2014–2015 | ||
| NQ HCIF General Partner, L.P. | TenPercentOwner | 4 | 2014–2015 | ||
| NQ HCIF GP, Ltd. | TenPercentOwner | 4 | 2014–2015 | ||
| Ruegg Curtis | Officer | EVP R&D and Tech Operations; EVP, Technical Operations | 31 | 2014–2016 | |
| SILVERNAIL LAUREN P | Officer | CFO & CBO; CFO, CBO & Secretary; CFO, Secretary & EVP Corp Dev.; CFO, Seretary & EVP Corp Dev. | 27 | 2014–2018 | |
| Tunnicliffe Jonathan | Director,TenPercentOwner | 5 | 2014–2015 | ||
| Waugh Jacob | Officer | Chief Scientific Officer | 6 | 2014–2015 | |
| WOOTEN RONALD J | Director,TenPercentOwner | 5 | 2014–2015 | ||
| Russell Angus C. | Director | 15 | 2014–2025 | ||
| PRYGOCKI MARK A SR | Director | 4 | 2014–2016 | ||
| Bertolino Arthur Peter | Officer | EVP and Chief Medical Officer | 5 | 2014–2015 | |
| Vickers Philip J. | Director | 12 | 2015–2022 | ||
| Joshi Abhay | Officer | Chief Operating Officer; COO, President of R&D; COO, President, R&D | 26 | 2015–2022 | |
| Gangolli Julian S | Director | 12 | 2016–2025 | ||
| Foley Mark J | Director; Director,Officer | CEO; CEO & President; Chief Executive Officer; President & CEO | 35 | 2017–2025 | |
| Zavodnick Todd Erik | Officer | CCO & President,; Chief Commercial Officer | 4 | 2017–2018 | |
| McDowell Caryn Gordon | Officer | SVP, GC & Secretary | 8 | 2018–2020 | |
| Allouche Cyril | Officer | Principal Accounting Officer; Principal Financial Officer | 12 | 2018–2019 | |
| Schilke Tobin | Officer | CFO; Chief Financial Officer | 44 | 2018–2025 | |
| Beraud Jill | Director | 9 | 2019–2025 | ||
| Nolet Chris | Director | 9 | 2019–2025 | ||
| Sjuts Dustin S | Officer | Chief Commercial Officer; President | 34 | 2019–2024 | |
| Moxie Dwight | Officer | CLO & GC; SVP, GC & Secretary | 20 | 2020–2025 | |
| Rankin Aubrey | Director; Director,Officer | President, Innovation & Tech | 16 | 2020–2022 | |
| Kolaja Carey OConnor | Director | 9 | 2021–2025 | ||
| Ware Olivia C | Director | 8 | 2021–2025 | ||
| Coric Vlad | Director | 5 | 2023–2025 | ||
| Hollander David | Officer | CMO & Global Therapeutics Lead | 3 | 2024–2025 | |
| Jordan Erica | Officer | Chief Commercial Officer | 3 | 2024–2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Revance Therapeutics, Inc. | TN | State business registries | name and state |
| Business registration | REVANCE THERAPEUTICS, INC | TN | State business registries | name and state |
| Business registration | REVANCE THERAPEUTICS, INC | TN | State business registries | name and state |
| Business registration | REVANCE THERAPEUTICS, INC. | TN | State business registries | name and state |
| Business registration | REVANCE THERAPEUTICS, INC. | TN | State business registries | name and state |
| Business registration | REVANCE THERAPEUTICS, INC. | TN | State business registries | name and state |
| Business registration | REVANCE THERAPEUTICS, INC. | TN | State business registries | name and state |
| Business registration | REVANCE THERAPEUTICS, INC. | TN | State business registries | name and state |
| Business registration | REVANCE THERAPEUTICS, INC. | TN | State business registries | EIN (EXACT, as the state registration reports it) |
| Federal award recipient | REVANCE THERAPEUTICS, INC. | TN | Federal spending (USAspending) | name and state |
| Lobbying client | REVANCE THERAPEUTICS INC. | TN | Federal lobbying (LDA) | name and state |
| Paying company | REVANCE THERAPEUTICS, INC. | TN | Open Payments (drug and device company payments) | name and state |
| SEC filer | Revance Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Revance Therapeutics, Inc. | TN | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | REVANCE THERAPEUTICS, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, TN first:
- KING PHARMACEUTICALS INC TN
- CUMBERLAND PHARMACEUTICALS INC TN
- Cryoport, Inc. TN
- HARROW, INC. TN
- Prescott Holdings, Inc. TN
- Melt Pharmaceuticals, Inc. TN
- PROVECTUS BIOPHARMACEUTICALS, INC. TN
- MorphoSys AG 2M
- Affimed N.V. 2M
- InflaRx N.V. 2M
In other datasets, the same topic (Health) in TN:
- Nonprofit: 2 MILLION DOGS 2 MILES INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health